Point72 Asset Management
CLDX icon

Point72 Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Point72 Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.36M Sell
117,217
-3,112,722
-96% -$101M ﹤0.01% 1853
2026
Q1 		$102M Buy
3,229,939
+1,471,582
+84% +$40.1M 0.13% 168
2025
Q4 		$47.8M Sell
1,758,357
-2,135,585
-55% -$56.2M 0.05% 428
2025
Q3 		$101M Buy
3,893,942
+1,092,221
+39% +$25.3M 0.17% 122
2025
Q2 		$57M Buy
2,801,721
+180,546
+7% +$3.51M 0.11% 220
2025
Q1 		$47.6M Buy
2,621,175
+105,203
+4% +$2.35M 0.11% 228
2024
Q4 		$63.6M Buy
2,515,972
+947,264
+60% +$25.7M 0.14% 168
2024
Q3 		$53.3M Sell
1,568,708
-369,283
-19% -$14.1M 0.14% 176
2024
Q2 		$71.7M Buy
1,937,991
+654,194
+51% +$24.7M 0.19% 146
2024
Q1 		$53.9M Sell
1,283,797
-1,472,325
-53% -$60.5M 0.13% 181
2023
Q4 		$109M Buy
2,756,122
+1,413,722
+105% +$41.6M 0.26% 79
2023
Q3 		$36.9M Buy
1,342,400
+157,600
+13% +$4.94M 0.11% 241
2023
Q2 		$40.2M Buy
1,184,800
+955,297
+416% +$32.2M 0.12% 208
2023
Q1 		$8.26M Sell
229,503
-276,297
-55% -$11.9M 0.03% 607
2022
Q4 		$22.5M Buy
505,800
+370,800
+275% +$13.2M 0.08% 316
2022
Q3 		$3.79M Buy
+135,000
New +$4.14M 0.02% 797
2021
Q2 		– Sell
-46,100
Closed -$950K – 983
2021
Q1 		$950K Buy
+46,100
New +$1.06M ﹤0.01% 816

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Point72 Asset Management's CLDX Position: Q2 2026 in Review

Point72 Asset Management reduced its Celldex Therapeutics (CLDX) stake by 96% in Q2 2026, selling an estimated $101M and leaving 117,217 shares worth $4.36M. The position accounts for ﹤0.01% of the portfolio, ranked #1853.

Point72 Asset Management first reported a position in CLDX in Q1 2021 and has held it in 17 quarters since. The position peaked at $109M in Q4 2023. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Point72 Asset Management held 117,217 shares of Celldex Therapeutics worth $4.36M as of Q2 2026.
  • Point72 Asset Management sold 3,112,722 Celldex Therapeutics shares in Q2 2026, an estimated $101M.
  • Celldex Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q2 2026, its #1853 holding.
  • Point72 Asset Management first reported a position in Celldex Therapeutics in Q1 2021 and has held it in 17 quarters since.
  • Point72 Asset Management's Celldex Therapeutics position peaked at $109M in Q4 2023.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.